ReviewCurrent obesity reports2025
A Multidisciplinary Perspective on Semaglutide Treatment and Medical Nutrition Therapy in Obesity Management.
Review in Current obesity reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials.Diabetes, obesity & metabolism · 2026Pooled it
- Integrating metabolic rehabilitation with incretin-based anti-obesity therapy: a narrative review of a multimodal strategy for sustainable weight loss.International journal of obesity (2005) · 2026Review
- Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care.The Journal of nutrition · 2026Article
- Mediterranean Dietary Pattern in Type 2 Diabetes Management: Pathways and Clinical Evidence.Biomedicines · 2026Review
- Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.Diabetes, obesity & metabolism · 2026Article
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.Current obesity reports · 2026Review
- Integrating patient-reported weight gain cause narratives into personalized obesity management: a data-driven approach with natural language processing and machine learning.Frontiers in nutrition · 2026Article
- Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.EXCLI journal · 2026Article
- Oral Adverse Effects of Semaglutide Therapy: A Narrative Review.Journal of International Society of Preventive & Community DentistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review explores the integration of semaglutide, a highly effective glucagon-like peptide-1 receptor agonist (GLP-1RA), with medical nutritional therapy (MNT) for the comprehensive management of obesity. Semaglutide promotes significant weight loss and metabolic improvement, but optimal outcomes often require combining this pharmacological treatment with tailored nutritional interventions. This review focuses on two prominent dietary strategies whose nutritional profiles may complement semaglutide's mechanisms of action: the Mediterranean diet (MD) and very-low-energy ketogenic therapy (VLEKT). RECENT
findingsThe MD emphasises balanced macronutrients and anti-inflammatory components, making it particularly suitable for individuals with uncomplicated obesity; it supports gradual and sustainable weight loss while mitigating inflammation and gastrointestinal side effects. Conversely, VLEKT, which induces nutritional ketosis, may be more appropriate for patients with significant cardiometabolic comorbidities, offering rapid and substantial fat mass reduction and improved glycaemic control. Both dietary approaches, when integrated with semaglutide therapy, have the potential to preserve lean body mass, reduce gastrointestinal adverse events, and enhance adherence through improved satiety and tolerability. The proposed integrated approach underscores the importance of personalised nutritional strategies guided by patient-specific metabolic, hormonal, and microbiota profiles, and calls for effective multidisciplinary collaboration among nutritionists, endocrinologists, and behavioural health professionals to optimise therapeutic outcomes. Ultimately, we emphasise that shifting the clinical focus from weight reduction alone to a targeted approach integrating semaglutide with evidence-based nutritional strategies may represent the most promising pathway towards sustainable obesity management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.